<DOC>
	<DOC>NCT00141089</DOC>
	<brief_summary>Tegaserod (HTF919) is an aminoguanidine indole compound and a member of a class of subgroup-selective 5-hydroxytryptamine (5-HT) agonists. The aim of this study was to evaluate the efficacy and safety of tegaserod on bowel habits in male patients with chronic constipation.</brief_summary>
	<brief_title>Assessment of Efficacy and Safety of Tegaserod in Male Patients With Chronic Constipation.</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Tegaserod</mesh_term>
	<criteria>A 6month history of constipation defined as &lt;3 complete spontaneous bowel movements per week and &gt;1 of the following symptoms &gt;25% of the time: hard stools, sensation of incomplete evacuation and straining Patients with cancer, inflammatory bowel disease or other structural bowel disease Past or current diagnosis of irritable bowel syndrome were excluded. Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Male patients, chronic constipation, tegaserod</keyword>
</DOC>